Atavistic Chemotherapy
Phase 2- Indications
- Advanced cancer, Metastatic cancer
Company intelligence / Profile preview
Dr. Frank Arguello Cancer Clinic
Bethesda, Maryland, United Statesatavisticchemotherapy.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The clinic is conducting a clinical trial (NCT02366884) for "Atavistic Chemotherapy" based on Dr. Arguello's theory of "Atavistic Metamorphosis." The treatment claims to target and eliminate cancer cells selectively using combinations of drugs conventionally used against bacterial, fungal, and protozoal cells. The trial claims patients can expect significant clinical response within three weeks and potential complete cancer eradication within six months[1][4].
- Therapeutic areas
- Oncology
- Modalities
- Combination of FDA-approved drugs (specific drugs not disclosed)
- Industry
- Non-Academic Healthcare
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Dr. Frank Arguello Cancer Clinic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dr. Frank Arguello Cancer Clinic.